DPC 817

Brand Name: Reverset



DPC 817, also known as Reverset, RVT, or D-D4FC, is a type of medicine called a nucleoside reverse transcriptase inhibitor (NRTI). NRTIs work by blocking reverse transcriptase, a protein that HIV needs to make more copies of itself.

HIV/AIDS-Related Uses

DPC 817 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. It is being studied for the treatment of HIV infection. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

Dosage Information

DPC 817 comes in enteric coated tablets and buffered oral solution.

Contraindications

Individuals should tell a doctor about any medical problems before taking this medicine.

Possible Side Effects

Along with its desired effects, DPC 817 may cause some unwanted effects. Further study is needed to determine the possible side effects of DPC 817. Individuals should tell a doctor if they experience side effects that are bothersome.

Drug and Food Interactions

A doctor should be notified of any other medications being taken, including prescription, nonprescription (over-the-counter), or herbal medications.

Clinical Trials

For information on clinical trials that involve DPC 817, visit the ClinicalTrials.gov web site at http://www.clinicaltrials.gov. In the Search box, enter: DPC 817 AND HIV Infections.

Manufacturer Information

DPC 817 Pharmasset, Inc. US Research Operations 1860 Montreal Road Tucker, GA 30084 (678) 395-0035

Reverset
Pharmasset, Inc.
US Research Operations
1860 Montreal Road
Tucker, GA 30084
(678) 395-0035

For More Information

Contact your doctor or an AIDSinfo Health Information Specialist:

- Via Phone: 1-800-448-0440 Monday Friday, 12:00 p.m. (Noon) 5:00 p.m. ET
- Via Live Help: http://aidsinfo.nih.gov/live_help Monday - Friday, 12:00 p.m. (Noon) - 4:00 p.m. ET